COLL

Business Context and Reporting Period

Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: Collegium is a biopharmaceutical company focused on pain management and ADHD treatments. Its portfolio includes Jornay PM (ADHD), Belbuca, Xtampza ER, Nucynta ER/IR (pain), and Symproic (opioid-induced constipation). The quarter reflects the full impact of the Ironshore Therapeutics acquisition (closed September 2024), which added the Jornay PM product line.

Key Financial Metrics

Note: Total Debt includes $600,281 in Term Notes (carrying value) and $237,429 in Convertible Senior Notes (carrying value) as of March 31, 2025.

Material Changes vs. Prior Period

• Revenue Growth: Net product revenues increased by $32.9 million (22.7%) year-over-year. This was primarily driven by $28.5 million in new revenue from Jornay PM following the Ironshore acquisition. Existing products (Nucynta, Xtampza, Belbuca) also saw modest growth due to lower gross-to-net adjustments and higher gross prices, partially offset by lower sales volumes.
• Profitability Decline: Despite revenue growth, Net Income decreased significantly from $27.7 million to $2.4 million. This was caused by a $21.0 million increase in intangible asset amortization (due to Jornay) and a $34.4 million increase in operating expenses (driven by headcount additions, sales/marketing for Jornay, and executive transition costs).
• Interest Expense: Interest expense rose to $20.8 million from $17.3 million, largely due to the assumption of a deferred royalty obligation from the Ironshore acquisition ($3.6 million impact).
• Liquidity: Cash and cash equivalents decreased by approximately $132 million compared to the prior year period, reflecting debt repayments and investment in marketable securities.

Guidance, Outlook, and Risks

• Outlook: Management believes current cash, cash equivalents, and marketable securities ($197.8 million total) combined with operating cash flows are sufficient to fund operations and debt service for the foreseeable future.
• Share Repurchases: The company has a $150 million repurchase program authorized through June 30, 2025. As of March 31, 2025, $90 million remained available. In May 2025, the Board authorized an accelerated share repurchase of $25 million.
• Key Risks:
  • Debt Obligations: Significant indebtedness ($613.5 million principal on Term Loan; $241.5 million on Convertible Notes) creates refinancing risk and limits flexibility.
  • Regulatory & Litigation: Ongoing patent litigation with Purdue (Xtampza ER, Nucynta) and generic competitors (Belbuca). Opioid-related investigations and potential state taxes on opioids remain a risk.
  • Supply Chain: Reliance on sole suppliers for active pharmaceutical ingredients (APIs) and third-party manufacturers. Potential shortages of controlled substances (e.g., methylphenidate for Jornay) due to DEA quotas.
  • Competition: Entry of new non-opioid analgesics (e.g., Vertex's suzetrigine) and generic competition.

Investor Verification Checklist

• Jornay PM Performance: Verify the sustainability of Jornay revenue growth and the impact of the deferred royalty obligation (7.4% to 9.7% royalty rate) on future margins.
• Debt Covenants: Review compliance with the 2024 Term Loan covenants, particularly regarding additional indebtedness and asset dispositions.
• Patent Litigation Status: Monitor the status of Purdue litigation regarding Xtampza ER and Nucynta, as well as generic challenges to Belbuca, which could impact long-term revenue.
• Share Repurchase Execution: Track the utilization of the remaining $90 million repurchase authorization and the impact of the new $25 million accelerated program on liquidity.
• Supply Chain Resilience: Assess any potential disruptions in the supply of controlled substances (Schedule II and III) due to DEA quota limitations.